Literature DB >> 10839374

Has an intensified treatment in the ambulance of patients with acute severe left heart failure improved the outcome?

M Gardtman1, L Waagstein, T Karlsson, J Herlitz.   

Abstract

The aim of this study was to evaluate short- and long-term outcome prior to and after the introduction of a more intensified treatment in the ambulance of patients with acute severe heart failure. Consecutive patients with acute severe heart failure transported by the mobile coronary care unit (MCCU) in the community of Göteborg prior to and after the introduction of an intensified treatment (nitroglycerine, continuous positive airway pressure (CPAP) and furosemide). One hundred and fifty-eight patients were evaluated during each period. The median age was 77 and 76.5 years, respectively, and 52% and 42% were women. The proportion of patients given nitroglycerine in the ambulance was 4% and 68% in the two periods; the proportion of patients treated with furosemide was 13% and 84%, respectively. CPAP was used in less than 1% during period 1 and in 91% during period 2. On admission of the ambulance 60% had fulminant pulmonary oedema during period 1 versus 78% during period 2 (p<0.0001). On admission to hospital the opposite was found, 93% during period 1 versus 76% during period 2 (p<0.0001). The median serum creatinine kinase (CK-MB) maximum activity was 13 microkat/l during period 1 and 8 microkat/l during period 2 (p = 0.007). However, the mortality during the first year remained high during both periods (39.2% and 35.8%, p = 0.64). It is concluded that a more intensive treatment in the ambulance of patients with acute severe heart failure seems to have resulted in an improvement in symptoms during transport and less myocardial damage. However, no significant improvement in long-term mortality was observed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839374     DOI: 10.1097/00063110-200003000-00004

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  5 in total

1.  CPAP for acute cardiogenic pulmonary oedema from out-of-hospital to cardiac intensive care unit: a randomised multicentre study.

Authors:  Laurent Ducros; Damien Logeart; Eric Vicaut; Patrick Henry; Patrick Plaisance; Jean-Philippe Collet; Claire Broche; Papa Gueye; Muriel Vergne; David Goetgheber; Pierre-Yves Pennec; Vanessa Belpomme; Jean-Michel Tartière; Sophie Lagarde; Marius Placente; Marie-Laurence Fievet; Gilles Montalescot; Didier Payen
Journal:  Intensive Care Med       Date:  2011-07-30       Impact factor: 17.440

Review 2.  Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.

Authors:  J Malcom O Arnold; Jonathan G Howlett; Paul Dorian; Anique Ducharme; Nadia Giannetti; Haissam Haddad; George A Heckman; Andrew Ignaszewski; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; John D Parker; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Vivek Rao; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2007-01       Impact factor: 5.223

Review 3.  Early identification and delay to treatment in myocardial infarction and stroke: differences and similarities.

Authors:  Johan Herlitz; Birgitta Wireklintsundström; Angela Bång; Annika Berglund; Leif Svensson; Christian Blomstrand
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-09-06       Impact factor: 2.953

4.  Out-of-hospital noninvasive ventilation: epidemiology, technology and equipment.

Authors:  John Scott Baird; Thyyar M Ravindranath
Journal:  Pediatr Rep       Date:  2012-04-24

Review 5.  Continuous positive airway pressure and noninvasive ventilation in prehospital treatment of patients with acute respiratory failure: a systematic review of controlled studies.

Authors:  Skule A Bakke; Morten T Botker; Ingunn S Riddervold; Hans Kirkegaard; Erika F Christensen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2014-11-22       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.